IL296828A - mtorc1 modulators and their uses - Google Patents
mtorc1 modulators and their usesInfo
- Publication number
- IL296828A IL296828A IL296828A IL29682822A IL296828A IL 296828 A IL296828 A IL 296828A IL 296828 A IL296828 A IL 296828A IL 29682822 A IL29682822 A IL 29682822A IL 296828 A IL296828 A IL 296828A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- salt
- alkyl
- optionally substituted
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Burglar Alarm Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001177P | 2020-03-27 | 2020-03-27 | |
| US202063001144P | 2020-03-27 | 2020-03-27 | |
| US202063001187P | 2020-03-27 | 2020-03-27 | |
| US202063019176P | 2020-05-01 | 2020-05-01 | |
| US202063054768P | 2020-07-21 | 2020-07-21 | |
| US202063054763P | 2020-07-21 | 2020-07-21 | |
| US202063054762P | 2020-07-21 | 2020-07-21 | |
| PCT/US2021/024536 WO2021195599A1 (en) | 2020-03-27 | 2021-03-26 | Mtorc1 modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296828A true IL296828A (en) | 2022-11-01 |
Family
ID=77892684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296828A IL296828A (en) | 2020-03-27 | 2021-03-26 | mtorc1 modulators and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11634432B2 (https=) |
| EP (1) | EP4126229A4 (https=) |
| JP (2) | JP7606591B2 (https=) |
| KR (2) | KR20250065937A (https=) |
| CN (2) | CN115776907B (https=) |
| AU (2) | AU2021241718B2 (https=) |
| CA (1) | CA3173722A1 (https=) |
| IL (1) | IL296828A (https=) |
| MX (1) | MX2022011964A (https=) |
| WO (1) | WO2021195599A1 (https=) |
| ZA (1) | ZA202210888B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) * | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| EP4688148A1 (en) * | 2023-04-07 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| JP2002508971A (ja) * | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
| ATE264863T1 (de) * | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| WO2006136175A2 (en) | 2005-06-22 | 2006-12-28 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor |
| GB0601406D0 (en) | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| US20110098241A1 (en) | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| CN103391780B (zh) * | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| US20160138027A1 (en) * | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| ES2857226T3 (es) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| CN113620978A (zh) | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| JP6793652B2 (ja) | 2015-09-03 | 2020-12-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN108926533B (zh) | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| US10478561B2 (en) | 2017-08-03 | 2019-11-19 | Minhong Yu | Wireless transmission system with integrated sensing capability |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| HRP20250197T1 (hr) | 2018-12-18 | 2025-04-11 | Novartis Ag | Derivati rapamicina |
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| US20220267352A1 (en) | 2021-01-22 | 2022-08-25 | Anakuria Therapeutics, Inc. | Rapamycin analogs and uses thereof |
-
2021
- 2021-03-26 CN CN202180038254.0A patent/CN115776907B/zh active Active
- 2021-03-26 EP EP21775952.1A patent/EP4126229A4/en active Pending
- 2021-03-26 IL IL296828A patent/IL296828A/en unknown
- 2021-03-26 CA CA3173722A patent/CA3173722A1/en active Pending
- 2021-03-26 AU AU2021241718A patent/AU2021241718B2/en active Active
- 2021-03-26 CN CN202510123209.5A patent/CN119954829A/zh active Pending
- 2021-03-26 MX MX2022011964A patent/MX2022011964A/es unknown
- 2021-03-26 KR KR1020257014654A patent/KR20250065937A/ko active Pending
- 2021-03-26 WO PCT/US2021/024536 patent/WO2021195599A1/en not_active Ceased
- 2021-03-26 KR KR1020227036354A patent/KR102805250B1/ko active Active
- 2021-03-26 JP JP2023502874A patent/JP7606591B2/ja active Active
-
2022
- 2022-03-01 US US17/683,549 patent/US11634432B2/en active Active
- 2022-06-03 US US17/832,240 patent/US11603377B2/en active Active
- 2022-10-03 ZA ZA2022/10888A patent/ZA202210888B/en unknown
-
2023
- 2023-03-08 US US18/180,517 patent/US20240002399A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218609A patent/JP7645431B2/ja active Active
-
2025
- 2025-06-25 AU AU2025204768A patent/AU2025204768C1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11603377B2 (en) | 2023-03-14 |
| CN115776907A (zh) | 2023-03-10 |
| US20220235069A1 (en) | 2022-07-28 |
| AU2025204768A1 (en) | 2025-07-17 |
| US20240002399A1 (en) | 2024-01-04 |
| JP7606591B2 (ja) | 2024-12-25 |
| CA3173722A1 (en) | 2021-09-30 |
| KR20250065937A (ko) | 2025-05-13 |
| JP7645431B2 (ja) | 2025-03-13 |
| WO2021195599A1 (en) | 2021-09-30 |
| EP4126229A1 (en) | 2023-02-08 |
| KR20230084095A (ko) | 2023-06-12 |
| AU2025204768B2 (en) | 2025-08-07 |
| CN119954829A (zh) | 2025-05-09 |
| AU2025204768C1 (en) | 2026-02-05 |
| US11634432B2 (en) | 2023-04-25 |
| AU2021241718A1 (en) | 2022-10-20 |
| AU2021241718B2 (en) | 2025-03-27 |
| CN115776907B (zh) | 2025-02-25 |
| BR112022019508A2 (pt) | 2022-11-16 |
| MX2022011964A (es) | 2022-12-02 |
| JP2025028197A (ja) | 2025-02-28 |
| EP4126229A4 (en) | 2024-04-17 |
| US20220332727A1 (en) | 2022-10-20 |
| KR102805250B1 (ko) | 2025-05-08 |
| ZA202210888B (en) | 2024-02-28 |
| JP2023530778A (ja) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025204768B2 (en) | Mtorc1 modulators and uses thereof | |
| BR112019026678A2 (pt) | indolinas espirocíclicas como moduladores de il-17 | |
| IL301756A (en) | Cystic fibrosis transmembrane regulator conductance modulators | |
| CN116322677B (zh) | Mtorc1调节剂及其用途 | |
| BR112020015509A2 (pt) | macrociclos como moduladores de regulador da condutância transmembrana da fibrose cística, composições farmacêuticas dos mesmos, sua utilização no tratamento da fibrose cística, e processo para sua produção | |
| AU2017359025A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors | |
| CN108135911A (zh) | 氧甾醇及其使用方法 | |
| CN109790146A (zh) | 药物化合物 | |
| EP3112369A1 (en) | Fused pyrazole derivative having autotaxin inhibitory activity | |
| CN114980975A (zh) | 二氢环戊二烯并异喹啉磺酰胺衍生物 | |
| BR122024006050B1 (pt) | MODULADORES DE mTORC1 E SEUS USOS | |
| BR112022019508B1 (pt) | MODULADORES DE mTORC1 E SEUS USOS | |
| TW202321244A (zh) | 一種Ｗｎｔ通路抑制劑化合物 | |
| BR122024006050A2 (pt) | Moduladores de mtorc1 e seus usos | |
| HK40096020B (zh) | Mtorc1调节剂及其用途 | |
| HK40096020A (zh) | Mtorc1调节剂及其用途 | |
| WO2025185734A1 (zh) | 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途 | |
| WO2025185736A1 (zh) | 一种多元螺环化合物的晶型、其制备方法和医药用途 | |
| CA3268315A1 (en) | Compound as inhibitor for sumo activating enzyme | |
| TW202537962A (zh) | 抑制α-V β-1整合素 | |
| EA049998B1 (ru) | Макроциклы, содержащие 1,3,4-оксадиазольное кольцо для применения в качестве модуляторов регулятора трансмембранной проводимости при муковисцидозе |